EcoR1 Capital, LLC
An institutional investment manager in San Francisco, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1587114.
- Reported value$2.06bn
- Positions33
Holdings: 33 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Zymeworks IncZYME | COM | 98985Y108 | 600 | 29.2% | 22,970,388 | Unchanged | |
| Anaptysbio IncANAB | COM | 032724106 | 532 | 25.9% | 7,880,094 | Unchanged | |
| Aktis Oncology IncAKTS | COM | 01021M104 | 155 | 7.6% | 4,824,469 | Unchanged | |
| CG Oncology IncCGON | COM | 156944100 | 106 | 5.2% | 1,494,300 | Added+392,300 | |
| Eton Pharmaceuticals IncETON | COM | 29772L108 | 78.6 | 3.8% | 2,171,938 | Unchanged | |
| Crispr Therapeutics AG | NAMEN AKT | H17182108 | 75.8 | 3.7% | 1,389,276 | Unchanged | |
| Oric Pharmaceuticals IncORIC | COM | 68622P109 | 72.9 | 3.5% | 6,728,116 | Unchanged | |
| First Tracks BiotherapeuticsTRAX | ORD SHS ADDED | 337185102 | 63.9 | 3.1% | 3,174,519 | New+3,174,519 | |
| Lakefront Biotherapeutics NVLKFT | SPON ADR | 36315X101 | 50.0 | 2.4% | 1,667,119 | Unchanged | |
| Neurogene IncNGNE | COM | 64135M105 | 40.0 | 1.9% | 1,271,342 | Unchanged | |
| CG Oncology IncCGON | COM | 156944100 | 39.9 | 1.9% | 561,500 | Call | New+561,500 |
| Stoke Therapeutics IncSTOK | COM | 86150R107 | 24.0 | 1.2% | 735,000 | Added+635,000 | |
| Fulcrum Therapeutics IncFULC | COM | 359616109 | 24.0 | 1.2% | 6,549,866 | New+6,549,866 | |
| Legend Biotech CorpLEGN | SPONSORED ADS | 52490G102 | 23.1 | 1.1% | 800,000 | New+800,000 | |
| Bridgebio Oncology TherapeutBBOT | COM NEW | 107924102 | 21.5 | 1.0% | 2,823,126 | Unchanged | |
| MBX Biosciences IncMBX | COM | 55287L101 | 21.4 | 1.0% | 388,500 | Reduced−388,500 | |
| Zenas Biopharma IncZBIO | COM | 98937L105 | 20.0 | 1.0% | 789,500 | Unchanged | |
| Atara Biotherapeutics IncATRA | COM NEW | 046513206 | 17.8 | 0.9% | 1,552,000 | Added+1,452,407 | |
| Relay Therapeutics IncRLAY | COM | 75943R102 | 13.1 | 0.6% | 697,948 | Reduced−1,206,814 | |
| Aura Biosciences IncAURA | COM | 05153U107 | 11.8 | 0.6% | 1,666,667 | New+1,666,667 | |
| Odyssey Therapeutics IncODTX | COMMON STOCK ADDED | 67613T104 | 10.4 | 0.5% | 555,555 | New+555,555 | |
| Eikon Therapeutics IncEIKN | COM | 282564103 | 9.6 | 0.5% | 732,606 | Unchanged | |
| Pharvaris N V | COM | N69605108 | 8.1 | 0.4% | 235,000 | New+235,000 | |
| Zura Bio Ltd | CLASS A ORD SHS | G9TY5A101 | 7.0 | 0.3% | 1,179,715 | Unchanged | |
| Phathom Pharmaceuticals IncPHAT | COM | 71722W107 | 6.8 | 0.3% | 625,000 | Unchanged | |
| Nurix Therapeutics IncNRIX | COM | 67080M103 | 6.6 | 0.3% | 270,000 | New+270,000 | |
| Erasca IncERAS | COM | 29479A108 | 6.0 | 0.3% | 330,000 | Reduced−570,000 | |
| Eloxx Pharmaceuticals IncELOX | COM NEW ADDED | 29014R301 | 5.6 | 0.3% | 400,000 | New+400,000 | |
| Aardvark Therapeutics IncAARD | COM | 002942100 | 2.3 | 0.1% | 396,194 | New+396,194 | |
| Helix Acquisition Corp III Usd | CL A ORD SHS | G4444S107 | 2.1 | 0.1% | 200,000 | Unchanged | |
| Mereo Biopharma Group plcMREO | SPON ADS | 589492107 | 0.3 | <0.1% | 1,000,000 | Reduced−12,368,855 | |
| Surrozen Inc | *W EXP 08/01/203 | 86889P117 | 0.1 | <0.1% | 4,444 | Unchanged | |
| Aardvark Therapeutics IncAARD | COM | 002942100 | 0.1 | <0.1% | 14,700 | Call | New+14,700 |
Sold out: 8 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Call | Sold out−410,800 |
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−6,000,000 | |
| Crinetics Pharmaceuticals in | COM | 22663K107 | 0.0 | 0.0% | 0 | Sold out−4,288,120 | |
| Ibio IncIBIO | COM NEW | 451033708 | 0.0 | 0.0% | 0 | Sold out−1,583,000 | |
| Jazz Pharmaceuticals plc | SHS USD | G50871105 | 0.0 | 0.0% | 0 | Sold out−1,706,469 | |
| Prelude Therapeutics IncPRLD | COM | 74065P101 | 0.0 | 0.0% | 0 | Sold out−947,049 | |
| Replimune Group IncREPL | COM | 76029N106 | 0.0 | 0.0% | 0 | Sold out−1,000,000 | |
| Xencor IncXNCR | COM | 98401F105 | 0.0 | 0.0% | 0 | Sold out−2,183,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0000935836-26-000415 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.